Edwards Lifesciences stock price target raised to $85 by UBS on strong TAVR sales

Investing.com - UBS raised its price target on Edwards Lifesciences (NYSE:EW) to $85.00 from $80.00 on Monday, while maintaining a Neutral rating following the company’s quarterly earnings report. The stock, currently trading at $79.29, is approaching its 52-week high of $83.00, with a market capitalization of $46.69 billion. InvestingPro data shows the company maintains a "GOOD" overall financial health score.

Edwards Lifesciences reported better-than-expected results across its product lines, with worldwide Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments exceeding consensus estimates by approximately 3% and 3.5%, respectively. The company’s robust performance is reflected in its impressive 9.5% revenue growth over the last twelve months.

The medical device company delivered first-half 2025 worldwide TAVR growth of approximately 6.6% on a constant currency basis, prompting management to raise its full-year 2025 guidance to 6%-7% growth from its previous forecast of 5%-7%.

Despite the improved outlook, UBS expressed uncertainty about Edwards’ ability to exceed its 5%-7% target growth rate based solely on its EARLY-TAVR program, suggesting that positive data from the PROGRESS trial, expected in late 2026, would be needed for sales growth to sustainably reach high single digits.

UBS concluded that Edwards Lifesciences’ current trading multiple of approximately 28 times price-to-earnings represents fair value given its near-to-mid-term growth trajectory, supporting the firm’s decision to maintain its Neutral rating.

In other recent news, Edwards Lifesciences reported robust financial results for the second quarter of 2025, with earnings per share (EPS) of $0.67, surpassing analysts’ expectations of $0.62. The company achieved revenue of $1.53 billion, exceeding the forecasted $1.49 billion. Edwards Lifesciences’ Transcatheter Aortic Valve Replacement (TAVR) business showed a 7.8% year-over-year growth, excluding foreign exchange impacts, contributing to the strong performance. RBC Capital raised its price target for the company to $89, citing the positive growth outlook and maintaining an Outperform rating. Piper Sandler also increased its price target to $90, while keeping an Overweight rating, following the impressive quarterly results. TD Cowen adjusted its price target to $84, maintaining a Hold rating, acknowledging the company’s top-line and bottom-line beats and the positive revisions to its full-year guidance. These developments highlight the company’s solid performance and the optimistic outlook from multiple analyst firms.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.